Search results for "Natalizumab"

showing 10 items of 36 documents

Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP

2014

Multiple Sclerosis Natalizumab Ty-STOPSettore MED/26 - Neurologia
researchProduct

Discontinuation of treatment with Natalizumab after 24 courses. Report from spontaneous, observational, prospective study (TYSTOP).

2013

Multiple Sclerosis Natalizumab TySTOPSettore MED/26 - Neurologia
researchProduct

Natalizumab Discontinuation after the 24th Course: Which Is Way? The TY-STOP Study

2013

Multiple SclerosisNatalizumab multiple sclerosisNatalizumabSettore MED/26 - NeurologiaMRi
researchProduct

TREATMENT CHOICE AFTER 24 NATALIZUMAB DOSES IN PATIENTS WITH MULTIPLE SCLEROSIS: A PROSPECTIVE OBSERVATIONAL STUDY, THE TY-STOP

2014

Multiple scleorsinatalizumabSettore MED/26 - Neurologia
researchProduct

Natalizumab therapy of relapsing-remitting multiple sclerosis: an evaluation of the safety profile and a comparison of efficacy with interferon beta …

2010

Natalizumab therapy multiple sclerosisSettore MED/26 - Neurologia
researchProduct

The Italian Natalizumab Registry: A 1-Year Follow-Up

2008

Natalizumab Multiple SclerosisSettore MED/26 - Neurologia
researchProduct

Clinical and instrumental predictors of efficacy of Natalizumab therapy in multiple sclerosis patients: a retrospective study from a single centre

2012

Natalizumab Multiple sclerosisSettore MED/26 - Neurologia
researchProduct

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML

2017

Objective:To examine retrospectively the effects of plasmapheresis (PLEX) on the survival and clinical outcomes of patients with multiple sclerosis (MS) and natalizumab (NTZ)–associated progressive multifocal leukoencephalopathy (PML).Methods:The medical literature was searched for the terms natalizumab and progressive multifocal leukoencephalopathy. A total of 193 international and 34 Italian NTZ-PML cases were included. Clinical outcome was determined by comparing the patients' clinical status at PML diagnosis with status after PML resolution. The effects on survival and clinical outcome of PLEX, sex, age, country, pre-PML Expanded Disability Status Scale score, NTZ infusion number, prior…

OncologyMaleJC virus030204 cardiovascular system & hematologymedicine.disease_causeLeukoencephalopathyDisability Evaluationneurology (clinical); progressive multifocal leukoencephalopathy; reconstitution inflammatory syndrome; multiple-sclerosis0302 clinical medicineNatalizumabImmunologic FactorLeukoencephalopathyRetrospective StudieMultiple SclerosiMedicinePlasmapheresiAdult; Disability Evaluation; Female; Humans; Immunologic Factors; Leukoencephalopathy Progressive Multifocal; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Plasmapheresis; PubMed; Retrospective Studies; Statistics Nonparametric; Treatment OutcomeProgressive multifocal leukoencephalopathyNatalizumabStatisticsLeukoencephalopathy Progressive MultifocalPlasmapheresisMiddle AgedTreatment OutcomeFemaleSettore MED/26 - Neurologiamedicine.drugHumanAdultmedicine.medical_specialtyPubMedMultiple SclerosisProgressive MultifocalStatistics Nonparametric03 medical and health sciencesImmune reconstitution inflammatory syndromeInternal medicineHumansImmunologic FactorsNonparametricprogressive multifocal leukoencephalopathy multiple sclerosis side effectRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosisRetrospective cohort studymedicine.diseaseImmunologyNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Four cases of progressive multifocal leukoencephalopathy in iatrogenic immunocompromised patients

2020

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system (CNS) caused by John Cunningham Virus (JCV). We report four PML cases in immunocompromised patients, respectively treated with (1) Natalizumab, (2) Rituximab, (3) autologous stem-cell transplantation, and (4) Tacrolimus. All patients underwent neurological examination, magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), JCV-DNA research on biological samples, and lymphocytes subpopulation study. All cases presented with motor, behavioural, and cognitive disorders. Visual, sensitive, and cerebellar deficits developed in three cases. MRI revealed widespread progressiv…

Pathologymedicine.medical_specialtyvirusesJC virusCase ReportJC virusmedicine.disease_causelcsh:RC346-429Multiple sclerosis03 medical and health sciences0302 clinical medicineNatalizumabDiagnosisMedicine030212 general & internal medicinelcsh:Neurology. Diseases of the nervous systemmedicine.diagnostic_testbusiness.industryMultiple sclerosisBrain biopsyProgressive multifocal leukoencephalopathyvirus diseasesMagnetic resonance imagingmedicine.diseaseTransplantationNeurologyNeuroradiologyRituximabJC virubusiness030217 neurology & neurosurgeryImmunosuppressionmedicine.drugDiagnosi
researchProduct

Return of disease activity after natalizumab therapy discontinuation in patients with multiple sclerosis: frequency and clinical and instrumental pre…

2012

Settore MED/26 - NeurologiaMultiple sclerosis natalizumab therapy
researchProduct